Third, a better clinical characterization of the alcoholic liver disease in a larger sample (subtypes and stages (i.e., fatty liver/steatosis, alcoholic steatohepatitis, and cirrhosis), pharmacological treatment, diet, and nutritional support, risk factors, etc.)is also required to identify the specific role of the ATX–LPA axis and its association with these clinical variables. This evidence concerns the gene LPA and alcoholic liver diseases.